SEC Form S-8 filed by Quince Therapeutics Inc.
As filed with the Securities and Exchange Commission on April 1, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Quince Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 90-1024039 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
611 Gateway Boulevard, Suite 273
South San Francisco, CA 94080
(415) 910-5717
(Address of Principal Executive Offices) (Zip Code)
Quince Therapeutics, Inc. 2019 Equity Incentive Plan
Quince Therapeutics, Inc. 2019 Employee Stock Purchase Plan
(Full title of the plans)
Dirk Thye
Chief Executive Officer
Quince Therapeutics, Inc.
611 Gateway Boulevard, Suite 273
South San Francisco, CA 94080
(415) 910-5717
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Please send copies of all communications to:
Gordon K. Ho
Cooley LLP
3175 Hanover Street
Palo Alto, California 94304
(650) 843-5000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
REGISTRATION OF ADDITIONAL SHARES
PURSUANT TO GENERAL INSTRUCTION E
Pursuant to General Instruction E of Form S-8, Quince Therapeutics, Inc. (the “Registrant”) is filing this registration statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) to register the offering of an additional 2,148,660 shares of Common Stock (the “Registered Shares”), par value $0.001 per share (“Common Stock”) of the Registrant. The Registered Shares being registered herein include (i) 1,718,928 shares of Common Stock issuable pursuant to the Registrant’s 2019 Equity Incentive Plan (the “2019 EIP”) and (ii) 429,732 shares of Common Stock issuable pursuant to the Registrant’s 2019 Equity Stock Purchase Plan (the “2019 ESPP”). These additional shares of Common Stock are securities of the same class as other securities for which previous registration statements on Form S-8 were filed with the Commission on May 9, 2019 (File No. 333-231307), March 16, 2020 (File No. 333-237199), March 1, 2021 (File No. 333-253743), March 1, 2022 (File No. 333-263186), and March 15, 2023 (File No. 333-270577) (collectively, the “Prior Registration Statements”). Accordingly, the contents of the Prior Registration Statements are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8. The Registered Shares which represent shares of Common Stock have become reserved for issuance as a result of the operation of the “evergreen” provisions in each of the 2019 EIP and 2019 ESPP, which provide that the total number of shares subject to such plan may be increased on the first day of each Registrant’s fiscal year pursuant to a specified formula.
In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.
PART II
ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE
The following documents filed by Registrant with the Commission are incorporated by reference into this Registration Statement:
(a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on April 1, 2024;
(b) The Registrant’s Current Reports on Form 8-K filed with the Commission on January 3, 2024, January 5, 2024, January 29, 2024, and February 15, 2024; and
(c) The description of the Registrant’s Common Stock contained in the registration statement on Form 8-A registering the Registrant’s Common Stock under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) filed with the Commission on May 1, 2019 and the description of the Registrant’s Series A Junior Participating Preferred Stock contained in the registration statement on Form 8-A registering the Registrant’s Series A Junior Participating Preferred Stock under Section 12 of the Exchange Act filed with the Commission on April 5, 2023, including any amendments or reports filed for purposes of updating such description.
All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
2
Item 8. Exhibits.
The following exhibits are filed herewith:
3
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on April 1, 2024.
QUINCE THERAPEUTICS, INC. |
/s/ Dirk Thye |
Dirk Thye |
Chief Executive Officer and Director |
Power of Attorney
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dirk Thye and Brendan Hannah, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated:
Name |
Title |
Date | ||
/s/ Dirk Thye Dirk Thye |
Chief Executive Officer and Director (Principal Executive Officer) |
April 1, 2024 | ||
/s/ Brendan Hannah Brendan Hannah |
Chief Business Officer and Chief Operating Officer (Principal Financial and Accounting Officer) |
April 1, 2024 | ||
/s/ David A. Lamond David A. Lamond |
Director | April 1, 2024 | ||
/s/ Margaret McLoughlin Margaret McLoughlin, Ph.D. |
Director | April 1, 2024 | ||
/s/ Una Ryan Una Ryan, OBE Ph.D. |
Director | April 1, 2024 | ||
/s/ Christopher J. Senner Christopher J. Senner |
Director | April 1, 2024 | ||
/s/ Luca Benatti Luca Benatti |
Director | April 1, 2024 | ||
/s/ Rajiv Patni Rajiv Patni |
Director | April 1, 2024 | ||
/s/ June Bray June Bray |
Director | April 1, 2024 |
4